Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (7070)	2/22/1999 9:54:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Monsanto's Celebrex Sales Seen Hitting $1 Billion In 1st Year By Thomas Burton, Staff Reporter 02/22/99 Dow Jones Business News CHICAGO -(Dow Jones)- A leading health-care analyst told Dow Jones that, based on the latest sales numbers, it now is "conservative" to predict that the Monsanto Co. arthritis-pain drug Celebrex will hit $1 billion in sales in its first year on the market. Meanwhile, those sales figures for Celebrex 's fifth week on the market show that it is closing in on the sales of impotence medication Viagra at a comparable time. Since Viagra is the No. 1-selling recent drug in achieving early sales, this means that Celebrex could easily become the all-time early top-seller among recent drugs, said analyst Hemant K. Shah. "At this point, it is conservative to say Celebrex will be a billion-dollar drug in its first year," said Shah, who in January told The Wall Street Journal that the drug's first-year sales could reach the $1 billion mark. NDC Health Information Services, which supplies marketing data to the pharmaceutical industry, told Dow Jones that Celebrex sales for the fifth week of marketing, ended Sunday Feb. 21, hit 155,000 prescriptions. Viagra achieved 310,000 prescriptions at the same point in its marketing history. But NDC's senior vice president, Shel Silverberg, told Dow Jones that the fifth week was the highest single week that Viagra achieved. And Celebrex is running at about five times the early sales of the cholesterol-medication Lipitor, which was No. 2 among recent new pharmaceutical products until Celebrex came along. Lipitor hit about 30,000 prescriptions during its fifth marketing week, in 1997, according to Silverberg. Lipitor is projected to be a $3 billion drug this year. Monsanto (MTC) co-markets Celebrex with Pfizer Inc. (PFE), the maker of Viagra and also the co-marketer of Warner-Lambert Co.'s (WLA) Lipitor. The joint marketing of Celebrex truly starts only this week, with sales just beginning. Yet without such "detailing" visits to doctors, Celebrex already has grabbed about 16% of the pain-treatment market, Shah said. Celebrex is the forerunner of a new class of arthritis drugs known as Cox-2 inhibitors. They act against an enzyme called cyclooxygenase-2, or Cox-2 for short. The Cox-2 drugs have special promise, in the view of many rheumatologists and internists, because clinical data suggest that these medications may not cause damage to patients' gastrointestinal tracts, as current drugs do. The next Cox-2 drug likely to be approved by the Food and Drug Administration is Merck & Co.'s (MRK) Vioxx.

To: Anthony Wong who wrote (7070)	2/23/1999 11:46:00 AM
From: Anthony Wong	Respond to of 9523

U.N. Report Says Drug Preferences Differ in Americas, Europe By John M. Goshko Washington Post Staff Writer Tuesday, February 23, 1999; Page A08 UNITED NATIONS, Feb. 22—A U.N.-related anti-narcotics agency reported today that people in North and South America consume large amounts of performance-enhancing drugs and stimulants, commonly called "uppers," while Europeans are the world's top users of so-called "downers," or stress-reducing drugs. These were among the trends discussed in the annual report of the International Narcotics Control Board, an independent panel that oversees implementation of United Nations drug control treaties. The board is responsible for monitoring and promoting compliance by signatory countries in controlling 116 narcotic drugs and 111 psychotropic substances, a category that includes hallucinogens, stimulants and depressants. The report notes that there is no clear-cut explanation for the differences in usage between Europe and the Americas. But it speculates that they could be linked to such factors as culture, the effects of advertising and differences in doctor-patient relationships. Noting the tendency of Americans, particularly in the United States, to make heavy use of a wide range of performance-enhancing drugs -- from muscle-building steroids to Ritalin, used to treat attention deficit disorder and hyperactivity in children, to Viagra, the anti-impotence drug -- the report says: "Such high use . . . could be at least partly explained by a prevalent sense of competition. Use of these drugs seems linked to culture and lifestyle." "In the Americas, particularly in the United States, performance-enhancing drugs are given to children to boost school performance or help them conform with the demands of school life," the report says. "They are also taken by adults to achieve the desired body image, boost athletic prowess and social skills or enhance sexual performance." Use by Americans of stimulants, particularly amphetamine-type substances for dieting and methylphenidate substances, such as Ritalin, amounts to an annual total of 330 million defined daily doses, compared with a total of about 65 million daily doses in all other parts of the world, the report says. The report finds no evidence that life in Europe is more stressful than in the Americas. Nevertheless, it says, stress-reducing drugs, called benzodiazepines by scientists, are used by as much as 10 percent of the populations in some European countries, with people older than 65 the heaviest users. It says, "Many Europeans in this age group have retired and no longer suffer professional stress, but may use the drugs to cope with isolation or threatening changes in life routine." And it warns, "But treating these symptoms with benzodiazepines can be dangerous, since these substances have a high abuse and dependency potential." The report also notes the board's opinion that the debate about medicinal use of cannabis, or marijuana, has been characterized "by ignorance, emotion and propaganda on all sides," and it recommends increased scientific research to better determine whether cannabis is beneficial in alleviating the unpleasant effects of various illnesses. In the United States, some states have adopted laws for freer use of cannabis, only to encounter fierce opposition from the White House and other federal narcotics control agencies. © Copyright 1999 The Washington Post Company washingtonpost.com